Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 19, 2026The American Journal of Cardiology

Transcatheter Aortic Valve Replacement Outcomes in Patients with Chronic Inflammatory Systemic Diseases

View Full Paper
Ask AI
Bookmark
Share

Key result

Chronic inflammatory diseases in TAVR are linked to similar mortality but ~69% more vascular complications.

  • P=0.73
  • n=2,880

Why the study?

The clinical impact of performing TAVR in patients with chronic inflammatory systemic diseases was not well reported.

Does the coexistence of chronic inflammatory systemic diseases lead to worse clinical outcomes in patients undergoing TAVR?

Population

2,880 TAVR patients at a single institution

Comparison

Patients with CIDs vs patients with no CIDs

Design

Single-center retrospective cohort study

Follow-up

One-year

Authors

BVBeni VermaInterventional CardiologyASAnita SadeghpourMedStar Washington Hospital CenterFHFarah Bani HaniGeorgetown University

Discussion

Loading...

Member takes

Implication

Similar one-year mortality supports TAVR in CID patients; leaves open effects on complications or longer-term outcomes.

Key Points

  • Evaluate the impact of chronic inflammatory systemic diseases on outcomes after transcatheter aortic valve replacement.
  • Retrospective analysis of 2,880 TAVR patients from 11/21/2011 to 03/29/2024.
  • Identified patients with chronic inflammatory diseases using ICD codes.
  • Compared clinical outcomes during inpatient and at one-year between CIDs and no-CID groups.
  • Higher proportion of females (61.6% vs 43.9%, p<0.001) and immunosuppressive therapy (5.9% vs 2.9%, p=0.02) among CIDs patients.
  • In-hospital mortality was similar (0.0% vs 1.7%; p=0.08); however, vascular complications (10.3% vs 6.1%, p=0.036) were more common in CIDs.
  • One-year mortality was comparable (8.9% vs 8.91%, log-rank p=0.73) between groups.

Study Design

Type

Cohort (n=2,880)

Multicenter

No

Structured PICO

Does the coexistence of chronic inflammatory systemic diseases lead to worse clinical outcomes in patients undergoing TAVR?

P
Population
2,880 patients undergoing transcatheter aortic valve replacement (mean age 79 years, 45% female), including 185 with chronic inflammatory systemic diseases, followed for one year.
E
Exposure
Transcatheter aortic valve replacement (TAVR) in patients with chronic inflammatory systemic diseases (CIDs)
C
Comparator
Transcatheter aortic valve replacement (TAVR) in patients without chronic inflammatory systemic diseases
O
Outcome
Clinical outcomes during inpatient and at one-year (including in-hospital mortality, vascular complications, unplanned vascular interventions, and one-year mortality)hard clinical

Main Result

Absolute Event Rate: 8.9% vs 8.91%

p-value: p=0.73

TAVR in patients with chronic inflammatory systemic diseases has comparable one-year mortality to those without, but carries a higher risk of vascular access complications.

Cite This Study

Verma et al. (2026) conducted a cohort in Aortic stenosis requiring transcatheter aortic valve replacement (n=2,880). Chronic inflammatory systemic diseases (CIDs) vs. No chronic inflammatory systemic diseases was evaluated on One-year mortality (p=0.73). In TAVR patients, chronic inflammatory systemic diseases were associated with similar one-year mortality (8.9% vs 8.91%, p=0.73) but higher vascular complications (10.3% vs 6.1%, p=0.036).

synapsesocial.com/papers/6a359a4add3be7785e70ee22https://doi.org/10.1016/j.amjcard.2026.06.010
View Full Paper
Ask AI
Bookmark
Share